Raydiant Oximetry, a clinical-stage medical device company focused on improving outcomes for mothers and babies during childbirth has closed an oversubscribed $7.5 million Series A3 extension round.

Raydiant Oximetry, Inc., a clinical-stage medical device company that develops medical technologies to improve outcomes for mothers and babies during childbirth, announces that the United States Food and Drug Administration (FDA) has approved the Investigational Device Exemption (IDE) of the Lumerah™ technology for an Early Feasibility Study (EFS) of pregnant women during labor and delivery.